FDA Advisory Panel Unanimously Recommends First mRNA Flu Vaccine

In a unanimous decision that could reshape how the world prepares for the annual flu season, an independent advisory panel to the U.S. Food and Drug Administration has voted 9-0 to recommend Moderna’s investigational mRNA influenza vaccine for adults aged 50 and older. The endorsement by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) marks a critical regulatory milestone for the shot, known as mFlusiva or mRNA-1010.[1][2][3]

If granted final approval by the FDA later this summer, mFlusiva would become the first mRNA-based seasonal flu vaccine available to the public. The milestone represents a significant expansion of the messenger RNA technology that gained global prominence during the COVID-19 pandemic, applying it to a virus that continues to cause hundreds of thousands of hospitalizations annually.[1][4][5]

For decades, the global standard for influenza vaccine production has relied on growing the virus in chicken eggs—a cumbersome process that requires health authorities to predict circulating strains up to six months in advance. This long lead time often results in a "strain mismatch," where the virus mutates before the vaccine is deployed, dropping real-world effectiveness to between 30% and 50%. Furthermore, the virus can adapt to the eggs during manufacturing, subtly changing its structure and reducing the vaccine's protective power.[3][5][8]

The mRNA approach bypasses the egg entirely. Instead of injecting a weakened virus, the vaccine delivers microscopic genetic instructions encased in lipid nanoparticles, teaching the body’s cells to produce specific influenza antigens. This direct encoding allows for a highly flexible and rapid manufacturing timeline, enabling scientists to match the vaccine to circulating strains much closer to the start of flu season.[1][3][7]

The committee’s endorsement was anchored by a massive Phase 3 clinical trial, which enrolled 40,805 adults across 11 countries during the 2024-2025 flu season. The results, published in The New England Journal of Medicine in May 2026, provided the primary evidence base for the FDA's review.[4][6][7]

In the trial, mRNA-1010 demonstrated a relative vaccine efficacy that was 26.6% higher than a licensed standard-dose seasonal flu vaccine in preventing laboratory-confirmed influenza-like illness. The data showed an even stronger protective effect against severe outcomes, with the mRNA shot demonstrating a 47.9% higher efficacy in preventing flu-related emergency room visits, hospitalizations, and urgent care use.[3][4][7]

"It is great to see the higher efficacy compared to existing vaccines," noted panel member Dr. Adam Berger during the daylong hearing, summarizing the consensus that the clinical evidence largely supports the vaccine's safety and effectiveness.[3]

However, the robust immune response generated by the mRNA platform comes with a trade-off in reactogenicity. Trial participants receiving mFlusiva reported higher rates of transient side effects compared to those receiving the standard-dose comparator. Injection-site pain occurred in 65.8% of mRNA recipients versus 29.8% for the standard dose, while fatigue and headache were also notably higher.[4][6]

Despite the increased frequency of these mild-to-moderate reactions, the FDA found no major safety issues. Serious adverse events were rare and comparable between the two groups, occurring in 2.2% of mRNA-1010 recipients and 1.9% of those receiving the standard vaccine.[4][5][6]

The unanimous vote caps off a turbulent regulatory journey for Moderna. In February 2026, the FDA initially issued a "refuse-to-file" letter, declining to review the application because the Phase 3 trial used a standard-dose vaccine as a comparator for adults over 65, rather than the high-dose vaccines typically recommended for that age group.[2][5]

The rejection sparked intense pushback from Moderna and drew scrutiny over shifting regulatory standards, eventually leading to a reversal by the FDA following high-level meetings. Under a revised agreement, Moderna is seeking full approval for adults aged 50 to 64, and accelerated approval for those 65 and older.[2][5]

To satisfy the conditions of the accelerated approval pathway for seniors, Moderna has committed to conducting a Phase 4 post-marketing confirmatory study to further demonstrate effectiveness against high-dose comparators in the older demographic.[2][7]

While the panel's vote was definitive, experts highlighted remaining areas of uncertainty. The Phase 3 efficacy data was gathered over a single flu season, leaving questions about how the vaccine will perform across multiple years with different dominant strains. Additionally, the durability of the immune response beyond the six-month follow-up window requires ongoing monitoring.[3][7][8]

The FDA is expected to make its final approval decision by its target date of August 5, 2026. If cleared, mFlusiva could be available for the upcoming fall respiratory virus season, offering older adults a highly precise, non-egg-based option in a market long dominated by conventional technologies.[1][5][8]